CSL Ltd Annual Report 2019

Focus on selected therapeutic areas – specialisation CSL’s business, including our R&D and in-market product portfolios, has advanced considerably over the past few years and looks very different to how it did 10 years ago. New and exciting opportunities allow us to address previously unmet patient needs and these continue to drive us each day. It is important that we have the organisational design and capabilities we need to allow us to achieve sustainable growth towards 2030 and beyond. CSL Behring is evolving and strengthening its therapeutic area (TA) focus to support continued innovation and continually refine ways in which products can meet patient needs. This will ensure a robust and diverse innovation pipeline based on a foundation of scientific excellence. Each TA will leverage data, networks and expertise to deliver value-based products to the market. The customer voice will be prominent early in the product lifecycle to optimise patient value and commercial viability. TAs were selected based on areas where we have the capabilities to be successful “in the CSL way” using our existing plasma assets and focusing on rare and serious diseases. The newmodel categorises our R&D and in-market portfolio into the following five TAs: –– immunology and neurology; –– haematology and thrombosis; –– cardiovascular and metabolic; –– transplant; and –– respiratory. We will continue to use our three primary platforms of plasma fractionation, recombinant technology and gene and cell therapies. Unmet medical needs will be identified in each TA, leading to the selection of an indication and the appropriate platform to develop new products, ultimately delivering on our promise to patients. CSL Limited Annual Report 2019 15 Innovation Our values We turn innovative thinking into solutions Lara Jupp, Scientist, Melbourne, Australia. Gene and Cell Therapy Recombinant Technology Plasma Fractionation Cardiovascular and Metabolic Respiratory Transplant Haematology and Thrombosis Immunology and Neurology